The abstract focuses on diagnostic and prognostic applications of molecular markers like IDH1/2, ATRX, and H3F3A mutations but doesn't address their mechanistic roles in glioma development. Understanding these pathways could reveal therapeutic targets beyond current biomarker applications. Gap type: unexplained_observation Source paper: Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. (2015, Neuropathol Appl Neurobiol, PMID:25944653)
Landscape Summary: How do molecular markers mechanistically drive glioma pathogenesis beyond their diagnostic utility? is a 0.8 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
How do molecular markers mechanistically drive glioma pathogenesis beyond their diagnostic utility? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: